Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 169

1.

Paraoxonase-1 suppresses experimental colitis via the inhibition of IFN-γ production from CD4 T cells.

Yamashita J, Iwamura C, Ito T, Narita M, Hara Y, Sasaki T, Masuda D, Takahashi M, Tsuchiya M, Hada K, Ishikawa M, Matsuo T, Ohno Y, Tanaka H, Maruyama H, Ogawa Y, Nakayama T.

J Immunol. 2013 Jul 15;191(2):949-60. doi: 10.4049/jimmunol.1201828. Epub 2013 Jun 14.

2.

Ameliorating effect of saporin-conjugated anti-CD11b monoclonal antibody in a murine T-cell-mediated chronic colitis.

Kanai T, Uraushihara K, Totsuka T, Nemoto Y, Fujii R, Kawamura T, Makita S, Sawada D, Yagita H, Okumura K, Watanabe M.

J Gastroenterol Hepatol. 2006 Jul;21(7):1136-42.

PMID:
16824065
3.

Comparative analysis of the effects of anti-IL-6 receptor mAb and anti-TNF mAb treatment on CD4+ T-cell responses in murine colitis.

Terabe F, Fujimoto M, Serada S, Shinzaki S, Iijima H, Tsujii M, Hayashi N, Nomura S, Kawahata H, Jang MH, Miyasaka M, Mihara M, Ohsugi Y, Kishimoto T, Naka T.

Inflamm Bowel Dis. 2011 Feb;17(2):491-502. doi: 10.1002/ibd.21384.

PMID:
20602470
4.

Involvement of interleukin 18 in Crohn's disease: evidence from in vitro analysis of human gut inflammatory cells and from experimental colitis models.

Maerten P, Shen C, Colpaert S, Liu Z, Bullens DA, van Assche G, Penninckx F, Geboes K, Vanham G, Rutgeerts P, Ceuppens JL.

Clin Exp Immunol. 2004 Feb;135(2):310-7.

5.

Therapeutic effect of anti-OX40L and anti-TNF-alpha MAbs in a murine model of chronic colitis.

Totsuka T, Kanai T, Uraushihara K, Iiyama R, Yamazaki M, Akiba H, Yagita H, Okumura K, Watanabe M.

Am J Physiol Gastrointest Liver Physiol. 2003 Apr;284(4):G595-603. Epub 2003 Jan 10.

6.

Glucocorticoid-induced leucine zipper is protective in Th1-mediated models of colitis.

Cannarile L, Cuzzocrea S, Santucci L, Agostini M, Mazzon E, Esposito E, Muià C, Coppo M, Di Paola R, Riccardi C.

Gastroenterology. 2009 Feb;136(2):530-41. doi: 10.1053/j.gastro.2008.09.024. Epub 2008 Sep 25.

PMID:
18996377
7.

IL-6 is required for the development of Th1 cell-mediated murine colitis.

Yamamoto M, Yoshizaki K, Kishimoto T, Ito H.

J Immunol. 2000 May 1;164(9):4878-82.

8.
9.
10.

CD69 regulates type I IFN-induced tolerogenic signals to mucosal CD4 T cells that attenuate their colitogenic potential.

Radulovic K, Manta C, Rossini V, Holzmann K, Kestler HA, Wegenka UM, Nakayama T, Niess JH.

J Immunol. 2012 Feb 15;188(4):2001-13. doi: 10.4049/jimmunol.1100765. Epub 2012 Jan 16.

11.

Administration of agonistic anti-4-1BB monoclonal antibody leads to the amelioration of inflammatory bowel disease.

Lee J, Lee EN, Kim EY, Park HJ, Chang CY, Jung DY, Choi SY, Lee SK, Lee KW, Kwon GY, Joh JW, Kim SJ.

Immunol Lett. 2005 Nov 15;101(2):210-6.

PMID:
16026855
12.
13.

Development of antigen induced colitis in SCID mice reconstituted with spleen derived memory type CD4(+) CD45RB(+) T cells.

Kweon MN, Takahashi I, Yamamoto M, Jang MH, Suenobu N, Kiyono H.

Gut. 2002 Mar;50(3):299-306.

14.

Mycophenolate Mofetil Modulates Differentiation of Th1/Th2 and the Secretion of Cytokines in an Active Crohn's Disease Mouse Model.

Lv QK, Liu JX, Li SN, Gao YJ, Lv Y, Xu ZP, Huang BX, Xu SY, Yang DX, Zeng YL, Liu DF, Wang W.

Int J Mol Sci. 2015 Nov 6;16(11):26654-66. doi: 10.3390/ijms161125985.

15.

Arsenic trioxide reduces 2,4,6-trinitrobenzene sulfonic acid-induced murine colitis via nuclear factor-κB down-regulation and caspase-3 activation.

Singer M, Trugnan G, Chelbi-Alix MK.

Innate Immun. 2011 Aug;17(4):365-74. doi: 10.1177/1753425910371668. Epub 2010 Aug 6.

PMID:
20693187
16.

B7 interactions with CD28 and CTLA-4 control tolerance or induction of mucosal inflammation in chronic experimental colitis.

Liu Z, Geboes K, Hellings P, Maerten P, Heremans H, Vandenberghe P, Boon L, van Kooten P, Rutgeerts P, Ceuppens JL.

J Immunol. 2001 Aug 1;167(3):1830-8.

17.

Ameliorating effect of anti-inducible costimulator monoclonal antibody in a murine model of chronic colitis.

Totsuka T, Kanai T, Iiyama R, Uraushihara K, Yamazaki M, Okamoto R, Hibi T, Tezuka K, Azuma M, Akiba H, Yagita H, Okumura K, Watanabe M.

Gastroenterology. 2003 Feb;124(2):410-21.

PMID:
12557147
18.

Feeding administration of Daikenchuto suppresses colitis induced by naive CD4+ T cell transfer into SCID mice.

Iwasa T, Ogino H, Nakamura K, Ihara E, Akiho H, Takayanagi R.

Dig Dis Sci. 2012 Oct;57(10):2571-9. Epub 2012 May 19.

PMID:
22610884
19.

Antibodies to interleukin 12 abrogate established experimental colitis in mice.

Neurath MF, Fuss I, Kelsall BL, Stüber E, Strober W.

J Exp Med. 1995 Nov 1;182(5):1281-90.

20.

Genetic and pharmacological targeting of TPL-2 kinase ameliorates experimental colitis: a potential target for the treatment of Crohn's disease?

Lawrenz M, Visekruna A, Kühl A, Schmidt N, Kaufmann SH, Steinhoff U.

Mucosal Immunol. 2012 Mar;5(2):129-39. doi: 10.1038/mi.2011.57. Epub 2011 Dec 7.

PMID:
22157885

Supplemental Content

Support Center